Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3982906, 9 pages
https://doi.org/10.1155/2017/3982906
Research Article

CYLD Deubiquitinase Negatively Regulates High Glucose-Induced NF-κB Inflammatory Signaling in Mesangial Cells

1Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, China
2Department of Kidney Endocrinology, The People’s Hospital of Qingbaijiang, Qingbaijiang, Sichuan 610300, China
3Faculty of Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau
4State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau
5Collaborative Innovation Center for Prevention and Treatment of Cardiovascular Disease of Sichuan Province, Southwest Medical University, Luzhou, Sichuan 646000, China

Correspondence should be addressed to Yang Long; moc.361@yl5230gnoloaix and Yong Xu; moc.nuyila@llywyx

Received 30 July 2017; Revised 12 October 2017; Accepted 22 October 2017; Published 12 November 2017

Academic Editor: Massimo Collino

Copyright © 2017 Yanhui Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. J. Dyson and E. A. Komives, “Role of disorder in IκB-NFκB interaction,” IUBMB Life, vol. 64, no. 6, pp. 499–505, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. B. Schröfelbauer, S. Polley, M. Behar, G. Ghosh, and A. Hoffmann, “NEMO Ensures Signaling Specificity of the Pleiotropic IKKβ by Directing Its Kinase Activity toward IκBα,” Molecular Cell, vol. 47, no. 1, pp. 111–121, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. Z. Ren, J. Cui, Z. Huo et al., “Cordycepin suppresses TNF-α-induced NF-κB activation by reducing p65 transcriptional activity, inhibiting IκBα phosphorylation, and blocking IKKγ ubiquitination,” International Immunopharmacology, vol. 14, no. 4, pp. 698–703, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. C. Gao, W. Huang, K. Kanasaki, and Y. Xu, “The role of ubiquitination and sumoylation in diabetic nephropathy,” BioMed Research International, vol. 2014, Article ID 160692, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Fraile, V. Quesada, D. Rodríguez, J. M. P. Freije, and C. López-Otín, “Deubiquitinases in cancer: new functions and therapeutic options,” Oncogene, vol. 31, no. 19, pp. 2373–2388, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S.-C. Sun, “CYLD: A tumor suppressor deubiquitinase regulating NF-B activation and diverse biological processes,” Cell Death & Differentiation, vol. 17, no. 1, pp. 25–34, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. J. H. Lim, H. Jono, K. Komatsu et al., “CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt,” Nature Communications, vol. 3, article no. 1776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Ma, H. Wu, CY. Zhao, U. Panchapakesan, C. Pollock, and SJ. Chadban, “Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy,” International Journal of Clinical and Experimental Pathology, vol. 7, pp. 481–495, 2014. View at Google Scholar
  9. M. Won, H. S. Byun, K. A. Park, and G. M. Hur, “Post-translational control of NF-κB signaling by ubiquitination,” Archives of Pharmacal Research, vol. 39, no. 8, pp. 1075–1084, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Ikeda, “Linear ubiquitination signals in adaptive immune responses,” Immunological Reviews, vol. 266, no. 1, pp. 222–236, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Huang, L. Xu, X. Zhou et al., “High glucose induces activation of NF-κB inflammatory signaling through IκBα sumoylation in rat mesangial cells,” Biochemical and Biophysical Research Communications, vol. 438, no. 3, pp. 568–574, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Huang, C. Yang, Q. Nan et al., “The proteasome inhibitor, MG132, attenuates diabetic nephropathy by inhibiting SnoN degradation in vivo and in vitro,” BioMed Research International, vol. 2014, Article ID 684765, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Gao, K. Aqie, J. Zhu et al., “MG132 ameliorates kidney lesions by inhibiting the degradation of smad7 in streptozotocin-induced diabetic nephropathy,” Journal of Diabetes Research, vol. 2014, Article ID 918396, 8 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Kovalenko, C. Chable-Bessia, G. Cantarella, A. Israël, D. Wallach, and G. Courtois, “The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination,” Nature, vol. 424, no. 6950, pp. 801–805, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Trompouki, E. Hatzivassillou, T. Tsichritzis, H. Farmer, A. Ashworth, and G. Mosialos, “CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members,” Nature, vol. 424, no. 6950, pp. 793–796, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Nikolaou, A. Tsagaratou, C. Eftychi, G. Kollias, G. Mosialos, and I. Talianidis, “Inactivation of the Deubiquitinase CYLD in Hepatocytes Causes Apoptosis, Inflammation, Fibrosis, and Cancer,” Cancer Cell, vol. 21, no. 6, pp. 738–750, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-C. Sun, “Deubiquitylation and regulation of the immune response,” Nature Reviews Immunology, vol. 8, no. 7, pp. 501–511, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J.-H. Lim, U.-H. Ha, C.-H. Woo, H. Xu, and J.-D. Li, “CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia,” Cellular Microbiology, vol. 10, no. 11, pp. 2247–2256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Hellerbrand, E. Bumes, F. Bataille, W. Dietmaier, R. Massoumi, and A. K. Bosserhoff, “Reduced expression of CYLD in human colon and hepatocellular carcinomas,” Carcinogenesis, vol. 28, no. 1, pp. 21–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Zhang, B. Stirling, S. T. Temmerman et al., “Impaired regulation of NF-κB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice,” The Journal of Clinical Investigation, vol. 116, no. 11, pp. 3042–3049, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Massoumi, K. Chmielarska, K. Hennecke, A. Pfeifer, and R. Fässler, “Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF- kappaB signaling,” Cell, vol. 125, no. 4, pp. 665–677, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. A. O'Donnell, E. Perez-Jimenez, A. Oberst et al., “Caspase 8 inhibits programmed necrosis by processing CYLD,” Nature Cell Biology, vol. 13, no. 12, pp. 1437–1442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Hövelmeyer, F. T. Wunderlich, R. Massoumi et al., “Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD,” The Journal of Experimental Medicine, vol. 204, no. 11, pp. 2615–2627, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Urbanik, R. J. Boger, T. Longerich et al., “Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice,” Journal of Hepatology, vol. 57, no. 5, pp. 995–1003, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. R. Brummelkamp, S. M. B. Nijman, A. M. G. Dirac, and R. Bernards, “Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB,” Nature, vol. 424, no. 6950, pp. 797–801, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Urbanik, B. C. Koehler, L. Wolpert et al., “CYLD deletion triggers nuclear factor-KB-signaling and increases cell death resistance in murine hepatocytes,” World Journal of Gastroenterology, vol. 20, no. 45, pp. 17049–17064, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Lim, Y. Jeong, S. Lee et al., “Identification of β-lapachone analogs as novel MALT1 inhibitors to treat an aggressive subtype of diffuse large B-cell lymphoma,” Journal of Medicinal Chemistry, vol. 58, no. 21, pp. 8491–8502, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. L. Bonapace, B. C. Bornhauser, M. Schmitz et al., “Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance,” The Journal of Clinical Investigation, vol. 120, no. 4, pp. 1310–1323, 2010. View at Publisher · View at Google Scholar · View at Scopus